ArticleDiabetes, obesity & metabolism2023

Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.

Kristoffer Nilsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.